Polyrizon Ltd. Announces Closing of $3.5 Million Registered Direct and Private Placements
Polyrizon Ltd., a NASDAQ-listed pre-clinical biotech firm focusing on intranasal protective hydrogels, announced the closing of a $3.5 million financing round via a registered direct offering and concurrent private placement with an institutional investor. The proceeds will be used for general corporate purposes and working capital to support ongoi…